These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34436526)

  • 1. Epigenetic deregulation in myeloid malignancies.
    Huang HT; Figueroa ME
    Blood; 2021 Aug; 138(8):613-624. PubMed ID: 34436526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next generation epigenetic modulators to target myeloid neoplasms.
    Sasca D; Guezguez B; Kühn MWM
    Curr Opin Hematol; 2021 Sep; 28(5):356-363. PubMed ID: 34267079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
    Ungerstedt JS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.
    Sapienza MR; Abate F; Melle F; Orecchioni S; Fuligni F; Etebari M; Tabanelli V; Laginestra MA; Pileri A; Motta G; Rossi M; Agostinelli C; Sabattini E; Pimpinelli N; Truni M; Falini B; Cerroni L; Talarico G; Piccioni R; Amente S; Indio V; Tarantino G; Brundu F; Paulli M; Berti E; Facchetti F; Dellino GI; Bertolini F; Tripodo C; Rabadan R; Pileri SA
    Haematologica; 2019 Apr; 104(4):729-737. PubMed ID: 30381297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of epigenetic changes in hematological malignancies.
    Lehmann U; Brakensiek K; Kreipe H
    Ann Hematol; 2004 Mar; 83(3):137-52. PubMed ID: 15064862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methyltransferases in hematologic malignancies.
    Li KK; Luo LF; Shen Y; Xu J; Chen Z; Chen SJ
    Semin Hematol; 2013 Jan; 50(1):48-60. PubMed ID: 23507483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies.
    Craddock C
    Cytotherapy; 2011 May; 13(5):516-7. PubMed ID: 21375421
    [No Abstract]   [Full Text] [Related]  

  • 8. The biology and clinical impact of genetic lesions in myeloid malignancies.
    Lindsley RC; Ebert BL
    Blood; 2013 Nov; 122(23):3741-8. PubMed ID: 23954890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic deregulation in myeloid malignancies.
    Meldi KM; Figueroa ME
    Transl Res; 2015 Jan; 165(1):102-14. PubMed ID: 24813528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on the epigenome in the myeloproliferative neoplasms.
    Kim E; Abdel-Wahab O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
    O'Sullivan JM; Harrison CN
    Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetics of hematopoiesis and hematological malignancies.
    Hu D; Shilatifard A
    Genes Dev; 2016 Sep; 30(18):2021-2041. PubMed ID: 27798847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic programming contributes to development of drug resistance in hematological malignancies.
    Wang QY; Zhong H
    Front Biosci (Landmark Ed); 2015 Jan; 20(4):728-42. PubMed ID: 25553475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of mutations in epigenetic regulators in myeloid malignancies.
    Woods BA; Levine RL
    Immunol Rev; 2015 Jan; 263(1):22-35. PubMed ID: 25510269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epigenetic therapy for hematologic malignancies].
    Kobayashi Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
    Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
    Front Immunol; 2020; 11():604142. PubMed ID: 33329600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetics in the hematologic malignancies.
    Fong CY; Morison J; Dawson MA
    Haematologica; 2014 Dec; 99(12):1772-83. PubMed ID: 25472952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress toward epigenetic therapies: the example of mixed lineage leukemia.
    Neff T; Armstrong SA
    Blood; 2013 Jun; 121(24):4847-53. PubMed ID: 23649466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The DNA methylation landscape of hematological malignancies: an update.
    Blecua P; Martinez-Verbo L; Esteller M
    Mol Oncol; 2020 Aug; 14(8):1616-1639. PubMed ID: 32526054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.